-
2
-
-
0024376173
-
-
Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49-4682-4689
-
Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49-4682-4689
-
-
-
-
3
-
-
27244457769
-
Raf: A strategic target for therapeutic development against cancer
-
Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005;23:6771-6790
-
(2005)
J Clin Oncol
, vol.23
, pp. 6771-6790
-
-
Beeram, M.1
Patnaik, A.2
Rowinsky, E.K.3
-
4
-
-
38049019119
-
Safety and anti-tumor activitiy of sorafenib (Nexavar®) in combination with other anticancer agents: A review of clinical trials
-
Takimoto CH, Awada A. Safety and anti-tumor activitiy of sorafenib (Nexavar®) in combination with other anticancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008;61:535-548
-
(2008)
Cancer Chemother Pharmacol
, vol.61
, pp. 535-548
-
-
Takimoto, C.H.1
Awada, A.2
-
5
-
-
33846260566
-
Sorafenib for the treatment of advanced renal cell carcinoma
-
Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006;12:7271-7278
-
(2006)
Clin Cancer Res
, vol.12
, pp. 7271-7278
-
-
Kane, R.C.1
Farrell, A.T.2
Saber, H.3
Tang, S.4
Williams, G.5
Jee, J.M.6
-
6
-
-
42349110073
-
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patient with metastatic renal cell carcinoma
-
in press
-
Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patient with metastatic renal cell carcinoma. Eur Urol in press 2007
-
(2007)
Eur Urol
-
-
Bhojani, N.1
Jeldres, C.2
Patard, J.J.3
Perrotte, P.4
Suardi, N.5
Hutterer, G.6
-
7
-
-
21344462378
-
Cutaneous side-effects of kinase inhibitors and blocking antibodies
-
Rober C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500
-
(2005)
Lancet Oncol
, vol.6
, pp. 491-500
-
-
Rober, C.1
Soria, J.C.2
Spatz, A.3
Le Cesne, A.4
Malka, D.5
Pautier, P.6
-
8
-
-
36148943535
-
Localized palmar-plantar epidermal hyperplasia: A previously undefined dermatologie toxicity to sorafenib
-
Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC Jr, Chaudhary UB. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologie toxicity to sorafenib. Oncologist 2007;12:1178-1182
-
(2007)
Oncologist
, vol.12
, pp. 1178-1182
-
-
Beldner, M.1
Jacobson, M.2
Burges, G.E.3
Dewaay, D.4
Maize Jr, J.C.5
Chaudhary, U.B.6
-
9
-
-
33751242294
-
Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib
-
Chung NM, Gutierrez M, Turner M. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib. Arch Dermatol 2006;142:865-866
-
(2006)
Arch Dermatol
, vol.142
, pp. 865-866
-
-
Chung, N.M.1
Gutierrez, M.2
Turner, M.3
-
11
-
-
34250863212
-
A case of leukocytoclastic vasculitis after influenza vaccination
-
Moon HS, Lee HK, Park K, Son SJ. A case of leukocytoclastic vasculitis after influenza vaccination. Korean J Dermatol 2007;45:515-517
-
(2007)
Korean J Dermatol
, vol.45
, pp. 515-517
-
-
Moon, H.S.1
Lee, H.K.2
Park, K.3
Son, S.J.4
-
12
-
-
41149096018
-
-
7th ed. New York: McGraw-Hill
-
Wolff K, Goldsmith LA, Katz SI, Gilcherst BA, Paller AS, Lefell DJ, et al. Fitzpatrick's dermatology in general medicine. 7th ed. New York: McGraw-Hill, 2007:1599-1606
-
(2007)
Fitzpatrick's dermatology in general medicine
, pp. 1599-1606
-
-
Wolff, K.1
Goldsmith, L.A.2
Katz, S.I.3
Gilcherst, B.A.4
Paller, A.S.5
Lefell, D.J.6
|